Journal of International Oncology››2021,Vol. 48››Issue (3): 156-163.doi:10.3760/cma.j.cn371439-20201116-00031
• Original Articles •Previous ArticlesNext Articles
Song Yang, Wang Bin*(), Xiao He, Chen Chuan, Wang Ge, Geng Mingying
Received:
2020-11-16Revised:
2020-11-23Online:
2021-03-08Published:
2021-03-25Contact:
Wang Bin E-mail:wangjianlinbin@163.comSong Yang, Wang Bin, Xiao He, Chen Chuan, Wang Ge, Geng Mingying. Predictive value of tumor regression rate after induction chemotherapy for survival of patients with locally advanced nasopharyngeal carcinoma[J]. Journal of International Oncology, 2021, 48(3): 156-163.
"
临床病理特征 | N1期 (n=37) |
N2-3期 (n=124) |
χ2/Z值 | P值 |
---|---|---|---|---|
性别 | ||||
女 | 10(27.0) | 38(30.6) | 0.178 | 0.673 |
男 | 27(73.0) | 86(69.4) | ||
T分期 | ||||
T1 | 0(0) | 11(8.9) | ||
T2 | 0(0) | 47(37.9) | 33.201 | <0.001 |
T3 | 21(56.8) | 39(31.5) | ||
T4 | 16(43.2) | 27(21.8) | ||
临床分期 | ||||
Ⅲ | 21(56.8) | 85(68.5) | 1.762 | 0.184 |
ⅣA | 16(43.2) | 39(31.5) | ||
鼻咽原发肿瘤诱导化疗后疗效评价 | ||||
CR | 3(8.1) | 20(16.1) | ||
PR | 15(40.5) | 61(49.2) | 3.793 | 0.150 |
SD | 19(51.4) | 43(34.7) | ||
颈部淋巴结诱导化疗后疗效评价 | ||||
CR | 5(13.5) | 5(4.0) | ||
PR | 14(37.8) | 80(64.5) | 10.442 | 0.009 |
SD | 18(48.6) | 38(30.6) | ||
PD | 0(0) | 1(0.8) | ||
年龄(岁) | 47(42,56) | 47(41,56) | -0.141 | 0.888 |
鼻咽原发肿瘤体积(cm3) | 3.3(2.3,3.8) | 2.8(1.8,3.6) | -1.679 | 0.093 |
颈部淋巴结转移肿瘤体积(cm3) | 2.5(1.8,3.5) | 4.8(3.0,6.8) | 5.483 | <0.001 |
鼻咽原发肿瘤诱导化疗后肿瘤退缩率(%) | 29.6(8.5,47.8) | 44.0(21.1,56.3) | 2.177 | 0.029 |
颈部淋巴结诱导化疗后肿瘤退缩率(%) | 30.4(0.0,51.4) | 42.6(16.7,52.0) | 1.722 | 0.085 |
"
临床病理特征 | T1-2期 (n=58) |
T3-4期 (n=103) |
χ2/Z值 | P值 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
性别 | ||||||||||||||||
女 | 14(24.1) | 34(33.0) | 1.396 | 0.237 | ||||||||||||
男 | 44(75.9) | 69(67.0) | ||||||||||||||
N分期 | ||||||||||||||||
N1 | 0(0) | 37(35.9) | ||||||||||||||
N2 | 50(86.2) | 58(56.3) | 27.135 | <0.001 | ||||||||||||
N3 | 8(13.8) | 8(7.8) | ||||||||||||||
临床病理特征 | T1-2期 (n=58) |
T3-4期 (n=103) |
χ2/Z值 | P值 | ||||||||||||
临床分期 | ||||||||||||||||
Ⅲ | 50(86.2) | 56(54.4) | 16.723 | <0.001 | ||||||||||||
ⅣA | 8(13.8) | 47(45.6) | ||||||||||||||
鼻咽原发肿瘤诱导化疗后疗效评价 | ||||||||||||||||
CR | 17(29.3) | 6(5.8) | ||||||||||||||
PR | 28(48.3) | 48(46.6) | 20.447 | <0.001 | ||||||||||||
SD | 13(22.4) | 49(47.6) | ||||||||||||||
颈部淋巴结诱导化疗后疗效评价 | ||||||||||||||||
CR | 3(5.2) | 7(6.8) | ||||||||||||||
PR | 40(69.0) | 54(52.4) | 4.437 | 0.187 | ||||||||||||
SD | 15(25.9) | 41(39.8) | ||||||||||||||
PD | 0(0) | 1(1.0) | ||||||||||||||
年龄(岁) | 48(41,55) | 47(41,57) | 0.326 | 0.744 | ||||||||||||
鼻咽原发肿瘤体积(cm3) | 2.0(1.5,2.9) | 3.2(2.3,3.8) | 4.315 | <0.001 | ||||||||||||
颈部淋巴结转移肿瘤体积(cm3) | 5.2(4.5,7.6) | 3.2(2.4,5.0) | -5.524 | <0.001 | ||||||||||||
鼻咽原发肿瘤诱导化疗后肿瘤退缩率(%) | 50.0(30.0,100.0) | 35.5(10.7,48.8) | -4.501 | <0.001 | ||||||||||||
颈部淋巴结诱导化疗后肿瘤退缩率(%) | 40.4(29.2,53.7) | 37.5(9.1,51.4) | -1.565 | 0.118 |
"
参数 | 单因素 | 多因素 | |||||
---|---|---|---|---|---|---|---|
HR值 | 95%CI | P值 | HR值 | 95%CI | P值 | ||
性别(男/女) | 0.988 | 0.542~1.802 | 0.970 | 1.043 | 0.558~1.949 | 0.895 | |
年龄(岁) | 0.994 | 0.968~1.020 | 0.646 | 0.987 | 0.961~1.015 | 0.367 | |
T分期(T3-4/T1-2) | 2.114 | 1.108~4.033 | 0.023 | 3.339 | 1.528~7.299 | 0.003 | |
N分期(N2-3/N1) | 1.204 | 0.618~2.344 | 0.585 | 1.344 | 0.634~2.852 | 0.441 | |
鼻咽原发肿瘤体积(cm3) | 1.158 | 0.921~1.452 | 0.203 | 1.235 | 0.948~1.609 | 0.118 | |
颈部转移淋巴结体积(cm3) | 1.127 | 1.036~1.227 | 0.005 | 1.221 | 1.094~1.363 | <0.001 | |
鼻咽原发肿瘤疗效(CR+PR/SD+PD) | 0.384 | 0.221~0.668 | 0.001 | 0.675 | 0.358~1.276 | 0.226 | |
颈部淋巴结转移肿瘤疗效(CR+PR/SD+PD) | 0.385 | 0.223~0.664 | 0.001 | 0.467 | 0.254~0.858 | 0.014 |
"
肿瘤退缩情况 | N1期(n=37) | N2-3期(n=124) | 交互项Wald P值 |
|||||
---|---|---|---|---|---|---|---|---|
HR值 | 95%CI | P值 | HR值 | 95%CI | P值 | |||
鼻咽原发肿瘤退缩率 | 0.048 | 0.004~0.644 | 0.022 | 0.178 | 0.056~0.564 | 0.003 | 0.386 | |
颈部淋巴结转移肿瘤退缩率 | 0.087 | 0.007~1.070 | 0.056 | 0.081 | 0.020~0.324 | <0.001 | 0.923 | |
鼻咽原发肿瘤疗效(CR+PR/SD+PD) | 0.174 | 0.037~0.830 | 0.028 | 0.422 | 0.228~0.781 | 0.006 | 0.353 | |
颈部淋巴结转移肿瘤疗效(CR+PR/SD+PD) | 0.154 | 0.033~0.725 | 0.017 | 0.439 | 0.238~0.813 | 0.009 | 0.234 |
"
肿瘤退缩情况 | T1-2期(n=58) | T3-4期(n=103) | 交互项 Wald P值 |
|||||
---|---|---|---|---|---|---|---|---|
HR值 | 95%CI | P值 | HR值 | 95%CI | P值 | |||
鼻咽原发肿瘤退缩率 | 0.595 | 0.093~3.802 | 0.584 | 0.121 | 0.033~0.444 | 0.001 | 0.161 | |
颈部淋巴结转移肿瘤退缩率 | 0.111 | 0.007~1.696 | 0.114 | 0.126 | 0.036~0.442 | 0.001 | 0.895 | |
鼻咽原发肿瘤疗效(CR+PR/SD+PD) | 1.458 | 0.319~6.655 | 0.627 | 0.297 | 0.150~0.588 | <0.001 | 0.062 | |
颈部淋巴结转移肿瘤疗效(CR+PR/SD+PD) | 0.953 | 0.258~3.523 | 0.943 | 0.329 | 0.173~0.625 | 0.001 | 0.161 |
[1] | Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015,136(5):E359-E386. DOI: 10.1002/ijc.29210. |
[2] | Cao CN, Luo JW, Gao L, et al. Update report of T4classification nasopharyngeal carcinoma after intensity-modulated radiotherapy: an analysis of survival and treatment toxicities[J]. Oral Oncol, 2015,51(2):190-194. DOI: 10.1016/j.oraloncology.2014.11.009. pmid:25434585 |
[3] | Al-Sarraf M, Leblanc M, Giri PGS, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase Ⅲ randomized Intergroup study 0099[J]. J Clin Oncol, 1998,16(4):1310-1317. DOI: 10.1200/JCO.1998.16.4.1310. pmid:9552031 |
[4] | Chen YP, Tang LL, Yang Q, et al. Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials[J]. Clin Cancer Res, 2018,24(8):1824-1833. DOI: 10.1158/1078-0432.CCR-17-2656. |
[5] | Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma[J]. New Engl J Med, 2019,381(12):1124-1135. DOI: 10.1056/NEJMoa1905287. |
[6] | Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial[J]. Lancet Oncol, 2016,17(11):1509-1520. DOI: 10.1016/S1470-2045(16)30410-7. doi:10.1016/S1470-2045(16)30410-7pmid:27686945 |
[7] | Song Y, Xiao H, Yang Z, et al. The predictive value of pre- and post-induction chemotherapy plasma EBV DNA level and tumor volume for the radiosensitivity of locally advanced nasopharyngeal carcinoma[J]. EXCLI J, 2017,16:1268-1275. DOI: 10.17179/excli2017-752. doi:10.17179/excli2017-752pmid:29333129 |
[8] | Tang LQ, Li CF, Li J, et al. Establishment and validation of prognostic nomograms for endemic nasopharyngeal carcinoma[J]. J Natl Cancer Inst, 2015, 108(1):djv291. DOI: 10.1093/jnci/djv291. |
[9] | Yang L, Hong S, Wang Y, et al. Development and external validation of nomograms for predicting survival in nasopharyngeal carcinoma patients after definitive radiotherapy[J]. Sci Rep, 2015,5:15638. DOI: 10.1038/srep15638. |
[10] | Zhang Y, Li WF, Mao YP, et al. Risk stratification based on change in plasma Epstein-Barr virus DNA load after treatment in nasopharyngeal carcinoma[J]. Oncotarget, 2016,7(8):9576-9585. DOI: 10.18632/oncotarget.7083. doi:10.18632/oncotarget.7083pmid:26840023 |
[11] | Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma[J]. N Engl J Med, 2004,350(24):2461-2470. DOI: 10.1056/NEJMoa032260. doi:10.1056/NEJMoa032260pmid:15190138 |
[12] | Wang WY, Twu CW, Chen HH, et al. Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels[J]. Cancer, 2013,119(5):963-970. DOI: 10.1002/cncr.27853. |
[13] | Peng H, Chen L, Li WF, et al. Tumor response to neoadjuvant chemotherapy predicts long-term survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: a secondary analysis of a randomized phase 3 clinical trial[J]. Cancer, 2017,123(9):1643-1652. DOI: 10.1002/cncr.30520. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||